Why Alzheimer trials fail: Removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult

Neurobiology of Aging

Volumn 35, Issue 5, 2014, Pages 969-974

  Rosenblum, William I ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Autopsies; Clinical trial failures; Cognitive decline; Correlation of soluble oligomers with cognitive decline; Interrelationship of senile plaque amyloid and soluble oligomers; Neurofibrillary tangles; Neurotoxic soluble oligomers; Senile plaques; Soluble ABeta amyloid; Synapses; Tau

Indexed keywords

ALZHEIMER'S DISEASE; AUTOPSIES; CLINICAL TRIAL FAILURES; COGNITIVE DECLINE; CORRELATION OF SOLUBLE OLIGOMERS WITH COGNITIVE DECLINE; INTERRELATIONSHIP OF SENILE PLAQUE AMYLOID AND SOLUBLE OLIGOMERS; NEUROFIBRILLARY TANGLES; NEUROTOXIC SOLUBLE OLIGOMERS; SENILE PLAQUES; SOLUBLE ABETA AMYLOID; SYNAPSES; TAU;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CLINICAL TRIALS AS TOPIC; HUMANS; PHOSPHORYLATION; PLAQUE, AMYLOID; POLYMERS; SOLUBILITY; TAU PROTEINS; TREATMENT FAILURE;

EID: 84893787111     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.10.085     Document Type: Review

References (61)

1. Calhoun M.E., Wiederhold K.-H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
2. Cohen R.M., Rezai-Zadeh K., Weitz T.M., Rentsendorj A., Gate D., Spivak I. Atransgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ, and frank neuronal loss. J.Neurosci. 2013, 33:6245-6256.
3. Cruz L., Urbanc B., Buldyrev S.V., Christie R., Gomez-Isla T., Havlin S., McNamara M., Stanley H.E., Hyman B.T. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1997, 94:7612-7616.
4. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. Aquantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J.Neurol. Sci. 1987, 78:151-164.
5. DeKosky S.T., Scheff S.W. Synapse loss infrontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
6. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
7. Eriksson P.S., Perfilieva E., Bjork-Eriksson T., Alborn A.-M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in adult human hippocampus. Nat. Med. 1998, 4:1313-1317.
8. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/β-amyloid ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
9. Geddes J.W., Monaghan D.T., Cotman C.W., Lott I.T., Kim R.C., Chui H.C. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 1985, 230:1179-1181.
10. Giaccone G., Pedrotti B., Migheli A., Verga L., Perez J., Rascagni G., Smith M.A., Perry G., DeGioia L., Selvaggini C., Salmona M., Ghiso J., Frangione B., Islam K., Bugiani O., Tagliavini F. Beta PP and tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. Am. J. Path. 1996, 148:79-87.
11. Giannakopoulos P., Herrman F.R., Bussiere T., Bouras C., Kovari E., Perl D.P. Tangle and neuron numbers but not amyloid load predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
12. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira B., Forette F., Orgogozo J.-M. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
13. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J.Neurosci. 1996, 16:4491-4500.
14. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010, 119:523-541.
15. Gouras G.K., Willen K., Tampellini D. Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ. Life Sci. 2012, 91:1153-1158.
16. Groopman J. Before Night Falls 2013, 38-43. The New Yorker, June 24.
17. Handoko M., Grant M., Kuskowski M., Zahs K.R., Wallin A., Blennow K., Ashe K.H. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 2013, 70:594-599.
18. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
19. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
20. Head C., Pop V., Vasilevko V., Hill M., Saing T., Sarsoza F., Nistor M., Christie L.A., Milton S., Glabe C., Barrett E., Cribbs D. Atwo year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J.Neurosci. 2008, 28:3555-3566.
21. Hefti F., Goure W.F., Jerecic J., Iverson K.S., Walicke P.A., Kraft G.A. The case for soluble Aβ oligomers as adrug target in Alzheimer's disease. Trends Pharmacol. Sci. 2013, 34:262-266.
22. Herskovits A.Z., Locascio J.J., Peskind E.R., Li G., Hyman B.T. Aluminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLos ONE 2013, 8:e67898.
23. Higuchi M., Iwata N., Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeautic interventions. Biochim. Biophys. Acta (BBA) 2005, 1751:60-67.
24. Hyman B.T., Kromer B.A., Van Hoesen G.W. Reinnervation of the hippocampus perforant pathway zone in Alzheimer's disease. Ann. Neurol. 1987, 21:259-267.
25. Hyman B.T., Marzloff K., Arriagada P.V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J.Neuropath. Exp. Neurol. 1993, 52:594-800.
26. SW transgenic mice develop age-related Aβ deposits and neuropil abnormalities but no neuronal loss in CA1. J.Neuropath. Exp. Neurol. 1997, 56:965-973.
27. Kirkwood C.M., Ciuchta J., Ikonomovic M.D., Fish K.N., Abrahamson E.E., Murray P.S., Klunk W.E., Sweet R.A. Dentritic spine density, morphology, and fibrillar actin content surrounding amyloid-β plaques in a mouse model of amyloid-β deposition. J.Neuropath. Exp. Neurol. 2013, 72:791-800.
28. Klein W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
29. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V. Amyloid beta protein immunotherapy neurtralizes Abeta oligomers that disrupt synaptic plasticity invivo. Nat. Med. 2005, 11:556-561.
30. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., Mansuy I.M. Aβ oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J.Neurosci. 2007, 27:7648-7653.
31. Koffie R.M., Meyer M.-L., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spire-Jones T.L. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A 2009, 106:4012-4017.
32. Koistinaho M., Ort M., Cimadevilla J.M., Vondrous R., Cordell B., Koistinaho J. Specific spatial learning deficits become severe with age in β-amyloid precursor protein trangenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. U.S.A 2001, 98:14675-14680.
33. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Yonkin L., Hyman B.Y., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J.Neurosci. 2002, 22:6331-6335.
34. Lannfelt, L., Zetterberg, H., Batsman S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R. Wilson, J., Ritchie, C.W. on behalf of the PBT2-201-Euro study group. 2008. 7;779-786.
35. Lue L.-F., Kuo Y.-M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Path. 1999, 155:853-862.
36. Maarouf C.L., Daugs D., Kokjohn T.A., Kalback W.M., Patton R.L., Luehrs D.C., Nicoll J.A.R., Sabbagh M.N., Beach T.G., Castano E.M., Roher A.E. The biochemical aftermath of anti-amyloid immunotherapy. Mol. Neurodegeneration 2012, 5:39-54.
37. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-868.
38. Meilandt W.J., Cisse M., Ho K., Wu T., Esposito L.A., Scearce-Levie K., Cheng I.H., Yu G.Q., Mucke L. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J.Neurosci. 2009, 9:2984-2988.
39. Meli G., Visintin M., Cannistraci I., Cattaneo A. Direct invivo intracellular selection of conformation sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J.Mol. Biol. 2009, 387:584-606.
40. Morris J.C., Price J.L. Pathological correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J.Mol. Neurosci. 2001, 17:101-118.
41. 42 immunization. J.Neuropath. Exp. Neurol. 2006, 65:1040-1048.
42. Niedowicz D.M., Beckett T.L., Matveev S., Weidner A.M., Baig I., Kryscio R.J., Mendiondo M.S., LeVine H., Keller J.N., Murphy M.P. Pittsburgh compound B and post mortem diagnosis of Alzheimer disease. Ann. Neurol. 2012, 72:564-570.
43. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., Laferia F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracelular Aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
44. Oddo S., Vasilevko V., Cacammo A., Kitazawas M., Cribbs D.H., LeFeria F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J.Biol. Chem. 2006, 281:39413-39423.
45. Oide T., Kinoshita T., Arima K. Regression stage senile plaques in the naturalcourse of Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2006, 32:539-556.
46. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., Kuo Y.-M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A.J., Beach T.G., Castano E.M., Roher A.E. Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients. Am. J. Path. 2006, 169:1048-1063.
47. Paula-Barbosa M.M., Saraiva A., Tavares M.A., Borges M.M., Verwer R.W. Alzheimer's disease: maintenance of neuronal and synaptic densities in frontal cortical layer II and III. Acta Neurol. Scand. 1986, 74:404-408.
48. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.R., Blennow K., Barakas J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2 double blind, placebo-controlled ascending dose study. Lancet Neurol. 2010, 9:363-372.
49. Roher A.E., Cribbs D.H., Kim R.C., Maarouf C.L., Whiteside C.M., Kokjohn T.A., Daugs I.D., Head E., Liebsack C., Serrano G., Belden C., Sab bagh M.N., Beach T.G. Bapineuzumab alters Aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. Plos One 2013, 8:e59735.
50. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
51. Serrano-Pozo A., Mielke M.L., Muzitansky A., Gomez-Isla T., Growdon J.H., Bacskai B.J., Betensky R.A., Frosch M.P., Hyman B.T. Stable size distribution of amyloid plaques over the course of Alzheimer disease. J.Neuropath. Exp. Neurol. 2012, 71:694-701.
52. Shankar G.M., Li N.S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
53. Solomon B., Koppel R., Franel D., Hanan-Aharon E. Disagreggation of Alzheimer beta-amyloid by site directed mAb. Proc. Natl. Acad. Sci. U.S.A 1997, 94:4109-4112.
54. Spalding K.L., Bergmann O., Alkass K., Bernard S., Salehpour M., Huttner H.B. Dynamics of hippocampal neurogenesis in adult humans. Cell 2013, 153:1219-1227.
55. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's diseases: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
56. Walsh D.M., Selkoe D.J. Aβ oligomers-a decade of discovery. J.Neurochem. 2007, 101:1172-1184.
57. Wang J., Chen L., Zhao Z., Jhao W., Qian X., Humala N. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J.Clin. Invest. 2007, 117:3393-3402.
58. Wang H.-W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of β amyloid inhibit long-term potentiation but not long term depression in rat dentate gyrus. Brain Res. 2002, 924:133-140.
59. Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hahimoto T., Iwatsubo T. Aβ immunotherapy: intracerebral sequestration of Aβ by anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. J.Neurosci. 2009, 29:11393-11398.
60. Zempel H., Thies E., Mandelkow E., Mandelkow E.-M. Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J.Neurosci. 2010, 30:11938-11950.
61. http://www./ct2/results?term=dominant+inherited%26;search=Search.